Skip to main content

What the FDA labels say about taking them together

Cytarabine and glasdegib

Glasdegib's FDA label of December 12, 2025 names cytarabine in its warnings and precautions section; the cytarabine label PlainMeds reads does not name glasdegib. The glasdegib label: “Of the 98 evaluable patients treated with DAURISMO 100 mg in combination with low-dose cytarabine in the clinical trial, 5% were found to have a QTc interval greater than 500 ms and 4% of patients had an increase from …”

Check it at the source: the cytarabine FDA label on DailyMed (effective April 7, 2025, Hospira, Inc.); the glasdegib FDA label on DailyMed (effective December 12, 2025, Pfizer Laboratories Div Pfizer Inc).

What does the cytarabine label say about glasdegib?

Cytarabine's label (effective April 7, 2025) does not name glasdegib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Cytarabine), Hospira, Inc., effective April 7, 2025 (SPL set e3a8c0e9-19ed-49b7-8464-11e8806f47fd), via openFDA; the full label on DailyMed

What does the glasdegib label say about cytarabine?

Glasdegib label, warnings and precautions

Of the 98 evaluable patients treated with DAURISMO 100 mg in combination with low-dose cytarabine in the clinical trial, 5% were found to have a QTc interval greater than 500 ms and 4% of patients had an increase from baseline QTc greater than 60 ms.

Source: FDA drug label (Daurismo), Pfizer Laboratories Div Pfizer Inc, effective December 12, 2025 (SPL set 204a6f7e-c9a4-472b-abd2-9527bda64d17), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

5Cytarabine generic labelers
0Glasdegib generic labelers
CytarabineGlasdegib
Labeled forLeukemia, lymphoma and myelomaLeukemia, lymphoma and myeloma
Boxed warningYesYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?